Gamma-Hydroxylactam Bioconjugation Reagents for Stable Multi-Functionalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioconjugation methods using maleimide suffer from side reactions such as hydrolysis and thiol exchange, limiting their versatility and functionalization capabilities.
Innovation Solution
Development of novel bioconjugation reagents based on an α,β unsaturated γ-hydroxylactam structure that allow for higher functionalization and stability, enabling reactive conjugations in both organic and biological contexts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If maleimide-based bioconjugation is used, then conjugation can be achieved, but side reactions such as hydrolysis and thiol exchange occur, reducing reliability
Solution Approach 1:
The patent changes the chemical structure parameter from maleimide to α,β-unsaturated γ-hydroxylactam, which fundamentally alters the reactivity profile. This structural modification eliminates the hydrolysis and thiol exchange side reactions while preserving the desired Michael addition conjugation pathway, thereby improving conjugation reliability without harmful byproducts
Solution Approach 2:
The patent converts the potential harm of side reactions into a benefit by designing a reagent where the α,β-unsaturated γ-hydroxylactam structure provides both the necessary reactivity for conjugation and inherent stability against hydrolysis. The lactam ring structure itself prevents the degradation pathways that plague maleimide, turning structural complexity into a protective feature
2Adaptability or versatility
If maleimide-based bioconjugation is used, then conjugation can be achieved, but the degree of functionalization is limited, reducing versatility
Solution Approach 1:
The patent creates a universal bioconjugation platform where the α,β-unsaturated γ-hydroxylactam core can accommodate multiple different functional groups (R1, R2, R3, R4, R5, R6) while maintaining consistent reactivity. This allows the same core structure to serve multiple functions: enabling high-degree functionalization, preventing side reactions, and providing a platform for diverse biomolecule conjugation applications
Solution Approach 2:
The patent segments the bioconjugation reagent into a stable core structure (α,β-unsaturated γ-hydroxylactam) and variable functional domains (R groups). This segmentation allows the core to provide consistent reliable conjugation while the R groups can be independently optimized for different functionalization needs, enabling high versatility without compromising stability
3Adaptability or versatility
If multi-functionalization is achieved with current methods, then multiple functions can be added, but multiple separate conjugation steps are required, increasing process complexity
Solution Approach 1:
The patent merges multiple conjugation capabilities into a single reagent molecule. The α,β-unsaturated γ-hydroxylactam structure can simultaneously present multiple reactive sites or functional groups that enable multi-functionalization in one conjugation step, eliminating the need for sequential conjugation operations and simplifying the overall process
Solution Approach 2:
The patent creates a universal conjugation platform where a single reagent type can achieve multiple functions through appropriate selection of R groups. This universal approach allows one reagent to replace what would traditionally require multiple specialized reagents and steps, reducing process complexity while maintaining versatility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new reagents provide improved stability, faster preparation, and higher functionalization in a single step, avoiding side reactions commonly associated with maleimide-based methods.
Implementation Method 1
Conjugation with proteins takes place via Michael addition of a cysteine thiol group present in the protein
Data Source
AI summary
The present invention in general relates to the field of bioconjugation. More in particular, the invention relates to novel bioconjugation reactants based on an α,β unsaturated γ-hydroxylactam structure, amongst others allowing a higher degree of functionalization compared to classical bioconjugation reactants such as maleimide. The present invention also provides methods of preparing the novel bioconjugation reactants, as well as uses thereof in human and/or veterinary medicine; and conjugation processes.